Blog

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Oct 10 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture partner Zylö Therapeutics…

Reunion Neuroscience Inc. Announces Executive Changes

Oct 10 • 2 min read

Reunion Neuroscience Inc. (TSX: REUN | NASDAQ: REUN), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary,…

The MindMed Chronicles: An Interview With Robert Barrow, the CEO of MindMed

Oct 8 • 2 min read

The following is a continuation of all our recent MindMed coverage. Over the past few weeks, we published a few conversations with Jake Freeman. Click here to watch part 1 of the Jake Freeman interview. Click here to watch part 2 of the Jake Freeman interview. Before that, it all began with a two-part interview…

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

Oct 7 • 1 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022, at 2:30 p.m. ET / 11:30 a.m. PT. The discussion will focus on Numinus’ recently…

Evan Levine, CEO of PsyBio Therapeutics, Sits in the Investor Hotseat on October 13th

Oct 7 • 2 min read

PsyBio Therapeutics ($PSYB) CEO, Evan Levine, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. Psybio has developed a portfolio of bio-medical chemistry development psycho-targeted compounds for the potential treatment for mental and neurological health. Evan himself is a leader encompassing more than two decades of in-depth expertise in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554